An interventional study of Fitz Frames 3-D Printed Glasses in Myopia, Amblyopia and Hyperopia, sponsored by Boston Children's Hospital. Terminated at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment
Funding was stopped from source before project could start intervention phase of trial
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.
Among the 342 studies in Myopia with a site in United States, this one is the 196th largest by enrollment of the 294 interventional ones that give a count, is one of 20 that started in 2024, is one of 243 with no phase, and was the 256th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ages 40+
Ohio State University · Sites in United States
Ages 18–38
CooperVision International Limited (CVIL) · Sites in United States, Spain
Ages 7–35
Stanford University · Sites in United States
Ages 22–59
Jaeb Center for Health Research · Sites in United States
Ages 5–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 15 · Phase 4 22
First in 1995; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 68 across the 294 interventional studies, 91 across the 46 observational. Of the 279 that completed or were terminated, 175 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
204 of 342 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
13 of the studies in Myopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07679048Rochester Institute of TechnologyMeasuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos | 2026-12-15 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 342 studies in Myopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Uncorrected refractive error is a leading cause of visual impairment in children and can impact vision, quality of life, and academic performance. Despite Boston Children's Hospital serving patients from a wide range of socioeconomic backgrounds, there are health disparities in access to eyeglasses as a consequence of patients' health insurance. The investigators will examine whether the use of an in-clinic app for 3-D printed glasses reduces disparities in access to eyeglasses for our patients on Medicaid. The intervention will address social determinants of health and improve pediatric health outcomes namely, how and when children having publicly funded health insurance receive eyeglasses. The short-term objectives are (1) to compare the time to receive glasses between publicly funded MassHealth eyeglasses and an in-clinic order of 3D printed glasses (2) to evaluate compliance with glasses wear in these two groups, and (3) to evaluate visual function and quality-of-life outcomes in these two groups. This prospective randomized control study will evaluate barriers to accessing eyeglasses in school-aged children. The investigators will recruit children enrolled in MassHealth and randomize them into two cohorts: (1) the control group will receive MassHealth glasses as per standard of care, through an optical shop of their choosing, or (2) the intervention group will use an app for immediately ordering glasses (paid for by the study) in clinic following their appointment. The investigators will evaluate the time needed to receive eyeglasses, compliance with glasses wear, quality of life, and visual outcomes between the cohorts at one-, three-, and six-month intervals. Through this project, the investigators will not only evaluate, quantify, and bring awareness to disparities in our patient population, but will also look toward finding a solution through the use of a novel application that addresses many of the barriers faced by patients insured through Medicaid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
Other: Fitz Frames 3-D Printed Glasses
(1) The control group will receive standard of care in which a prescription for glasses will be dispensed as a paper copy prescribed by the examiner before randomization. The research assistant will use a script (attached) that instructs families how to procure glasses traditionally through Masshealth. The participant/family will be instructed to bring the paper prescription to an optical shop that carries MassHealth frames. A printout of local optical shops that carry MassHealth frames will be provided to the patient.
The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
Compliance
Glasses compliance will be assessed with self-reported calendar
Time frame: Six months
Quality of Life Questionnaire
Quality of life measures using the PedEyeQ
Time frame: Baseline, will be collected at enrollment visit
Distance visual acuity
Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)
Time frame: Baseline, will be collected at enrollment visit
Distance visual acuity
Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)
Time frame: 0-3 Months, will be collected at 3 month visit
Distance visual acuity
Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)
Time frame: 3-6 Months, will be collected at 6 month visit
Stereoacuity
Stereo Fly test
Time frame: Baseline, will be collected at enrollment visit
Stereoacuity
Stereo Fly test
Time frame: 0-3 Months, will be collected at 3 month visit
Stereoacuity
Stereo Fly test
Time frame: 3-6 Months, will be collected at 6 month visit
Ocular alignment
Alternative prism cover test at distance and at near
Time frame: Baseline, will be collected at enrollment visit
Ocular alignment
Alternative prism cover test at distance and at near
Time frame: 0-3 Months, will be collected at 3 month visit
Ocular alignment
Alternative prism cover test at distance and at near
Time frame: 3-6 Months, will be collected at 6 month visit
Near point of convergence
Near point of convergence (break point and recovery) will be measured using an accommodative target
Time frame: Baseline, will be collected at enrollment visit
Near point of convergence
Near point of convergence (break point and recovery) will be measured using an accommodative target
Time frame: 0-3 Months, will be collected at 3 month visit
Near point of convergence
Near point of convergence (break point and recovery) will be measured using an accommodative target
Time frame: 3-6 Months, will be collected at 6 month visit
Near visual acuity
Near visual acuity will be measured at 40 cm using the Rosenbaum card
Time frame: Baseline, will be collected at enrollment visit
Near visual acuity
Near visual acuity will be measured at 40 cm using the Rosenbaum card
Time frame: 0-3 Months, will be collected at 3 month visit
Near visual acuity
Near visual acuity will be measured at 40 cm using the Rosenbaum card
Time frame: 3-6 Months, will be collected at 6 month visit
Quality of Life Questionnaire- PedEyeQ
Quality of life measures using the PedEyeQ
Time frame: 0-3 Months, will be collected at 3 month visit
Quality of Life Questionnaire- PedEyeQ
Quality of life measures using the PedEyeQ
Time frame: 3-6 Months, will be collected at 6 month visit
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in May 2025, 13 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Feb 2023 → Apr 2024, primary completion Nov 2023 → May 2025 and completion Dec 2023 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Funding was stopped from source before project could start intervention phase of trial
Funding was stopped from source before project could start intervention phase of trial
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.